NCT02962063 2025-09-05
Durvalumab, an Anti-PDLI Antibody, and Tremelimumab, an Anti-CTLA4 Antibody, and Chemoradiation Before Surgery for Esophageal Cancer
Memorial Sloan Kettering Cancer Center
Phase 1/2 Active not recruiting
Clinical Trials
4 trialsNCT04929392 2025-09-04
Chemoradiation and Pembrolizumab Followed by Pembrolizumab and Lenvatinib Before Surgery for the Treatment of Non-metastatic Esophageal or Esophageal/Gastroesophageal Junction Cancer
City of Hope Medical Center
Phase 2 Active not recruiting
NCT06642506 2024-11-12
Oncometabolome and MALDI-MSI in Upper GI Carcinomas - Chemosensitivity in Esophageal Carcinoma
Ludwig-Maximilians - University of Munich
Active not recruiting
NCT02509286 2024-05-08
ESOPEC
University Hospital Schleswig-Holstein
Phase 3 Active not recruiting